{"nctId":"NCT02352948","briefTitle":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","startDateStruct":{"date":"2015-01-13","type":"ACTUAL"},"conditions":["Non - Small Cell Lung Cancer NSCLC"],"count":597,"armGroups":[{"label":"MEDI4736 (durvalumab) monotherapy in Sub-study A","type":"EXPERIMENTAL","interventionNames":["Drug: MEDI4736 (durvalumab)"]},{"label":"Standard of Care in Sub-study A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vinorelbine","Drug: Gemcitabine","Drug: Erlotinib"]},{"label":"MEDI4736 (durvalumab) + tremelimumab in Sub-study B","type":"EXPERIMENTAL","interventionNames":["Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)"]},{"label":"Standard of Care in Sub-study B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vinorelbine","Drug: Gemcitabine","Drug: Erlotinib"]},{"label":"MEDI4736 (durvalumab) monotherapy in Sub-study B","type":"EXPERIMENTAL","interventionNames":["Drug: MEDI4736 (durvalumab)"]},{"label":"tremelimumab in Sub-study B","type":"EXPERIMENTAL","interventionNames":["Drug: tremelimumab (anti-CTLA4)"]}],"interventions":[{"name":"MEDI4736 (durvalumab)","otherNames":[]},{"name":"Vinorelbine","otherNames":[]},{"name":"Gemcitabine","otherNames":[]},{"name":"Erlotinib","otherNames":[]},{"name":"MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)","otherNames":[]},{"name":"tremelimumab (anti-CTLA4)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged at least 18 years\n* Documented evidence of NSCLC (Stage IIIB/ IV disease)\n* Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC\n* World Health Organization (WHO) Performance Status of 0 or 1\n* Estimated life expectancy more than 12 weeks\n\nExclusion Criteria:\n\n* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4\n* Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)\n* Active or prior documented autoimmune disease within the past 2 years\n* Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIV\n* Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) \\>Grade 2 from previous anti-cancer therapy\n* Known EGFR TK activating mutations or ALK rearrangements\n* Any prior Grade â‰¥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\>Grade 1\n* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"The OS was defined as the time from the date of randomization until death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"6.8","spread":null},{"groupId":"OG002","value":"11.5","spread":null},{"groupId":"OG003","value":"8.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"3.5","spread":null},{"groupId":"OG003","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"OS, Contribution of the Components Analysis of Sub-study B","description":"The OS was defined as the time from the date of randomization until death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"6.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Alive at 12 Months (OS12)","description":"The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"31.3","spread":null},{"groupId":"OG002","value":"49.5","spread":null},{"groupId":"OG003","value":"38.8","spread":null},{"groupId":"OG004","value":"43.6","spread":null},{"groupId":"OG005","value":"41.2","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS, Contribution of the Components Analysis of Sub-study B","description":"The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"14.9","spread":null},{"groupId":"OG003","value":"6.8","spread":null},{"groupId":"OG004","value":"15.4","spread":null},{"groupId":"OG005","value":"6.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"12.2","spread":null},{"groupId":"OG003","value":"10.8","spread":null},{"groupId":"OG004","value":"10.0","spread":null},{"groupId":"OG005","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Alive and Progression Free at 6 Months (APF6)","description":"The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"24.1","spread":null},{"groupId":"OG002","value":"31.5","spread":null},{"groupId":"OG003","value":"27.6","spread":null},{"groupId":"OG004","value":"27.2","spread":null},{"groupId":"OG005","value":"14.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Alive and Progression Free at 12 Months (APF12)","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":null},{"groupId":"OG001","value":"9.9","spread":null},{"groupId":"OG002","value":"20.6","spread":null},{"groupId":"OG003","value":"8.0","spread":null},{"groupId":"OG004","value":"15.0","spread":null},{"groupId":"OG005","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to Second Progression (PFS2) of Sub-study B","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"8.0","spread":null},{"groupId":"OG003","value":"5.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":62},"commonTop":["Decreased appetite","Diarrhoea","Nausea","Fatigue","Asthenia"]}}}